Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02125877 · ClinicalTrials.gov registry record · Phase 2
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT02125877 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 173 participants.
The verdict
NCT02125877, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
Assessed the new film-coated tablet formulation to the currently approved dispersible tablet formulation with regards to overall safety, Gastrointestinal (GI) tolerability, palatability, satisfaction and compliance
Interventions
- DRUG Deferasirox dispersible tablet
- DRUG Defearisox film-coated tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2014-07-08 |
| Est. Completion | 2016-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02125877
The ClinicalTrials.gov registry entry for NCT02125877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Deferasirox dispersible tablet is the first listed.
NCT02125877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02125877 about?
NCT02125877 is a clinical study titled "Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)". Assessed the new film-coated tablet formulation to the currently approved dispersible tablet formulation with regards to overall safety, Gastrointestinal (GI) tolerability, palatability, satisfaction and compliance
What is the current status of trial NCT02125877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2014-07-08. Estimated completion is 2016-02-24.
What interventions are being tested in trial NCT02125877?
The interventions under investigation include: Deferasirox dispersible tablet (DRUG), Defearisox film-coated tablet (DRUG).
Who is sponsoring clinical trial NCT02125877?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.